PMID- 33103312
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20220531
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 47
IP  - 1
DP  - 2021 Jan
TI  - Management of recurrent granulosa cell tumor of the ovary: Contemporary 
      literature review and a proposal of hyperthermic intraperitoneal chemotherapy as 
      novel therapeutic option.
PG  - 44-51
LID - 10.1111/jog.14494 [doi]
AB  - Granulosa cell tumors of the ovary (GCT) are the most common type of sex cord 
      stromal tumors. Although most of patients are diagnosed at early stage and has 
      favorable 5-year overall survival rate, 16-23% of GCT ultimately develop 
      recurrent disease. Recurrences are characterized by disseminated peritoneal 
      metastasis. The treatment options include systemic chemotherapy, secondary CRS or 
      palliative localized radiation therapy have not yet standardized due to the 
      rarity of disease. Aggressive CRS followed up by hyperthermic intraperitoneal 
      chemotherapy (HIPEC) has been shown to provide benefit in other peritoneal 
      disease but limited data available for recurrent GCT. We have a case of recurrent 
      Adult-type GCT (AGCT) who was treated with CRS followed by HIPEC with mitomycin C 
      and doxorubicin. The patient has no evidence of recurrence for approximately 
      11 years. An electronic search of the PubMed database with the following search 
      terms: GCT, HIPEC showed that there were total 21 patients with recurrent GCT 
      treated in seven different studies and 13 of 21 (61.9%) patients had no evidence 
      of disease during follow-up ranging from 6 to 100 months. Three patients (14.2%) 
      died of the disease. Six studies used cisplatin for HIPEC. At least 76.2% (16 of 
      21, data not available for five patients) had complete cytoreduction with total 
      16 cases of perioperative complications but no perioperative mortality was 
      observed. Although further investigation is needed, we propose that CRS and HIPEC 
      can be an effective therapeutic option for recurrent GCT at experienced 
      institutions.
CI  - (c) 2020 Japan Society of Obstetrics and Gynecology.
FAU - Yasukawa, Maya
AU  - Yasukawa M
AD  - Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, 
      Washington, District of Columbia, USA.
FAU - Matsuo, Koji
AU  - Matsuo K
AD  - Division of Gynecology Oncology, Department of Obstetrics and Gynecology, 
      University of Southern California, Los Angeles, California, USA.
AD  - Norris Comprehensive Cancer Center, University of Southern California, Los 
      Angeles, California, USA.
FAU - Matsuzaki, Shinya
AU  - Matsuzaki S
AD  - Division of Gynecology Oncology, Department of Obstetrics and Gynecology, 
      University of Southern California, Los Angeles, California, USA.
FAU - Dainty, Louis A
AU  - Dainty LA
AD  - Regional Director of Gynecologic Oncology at Georgetown Lombardi Comprehensive 
      Cancer Center, Chief of Gynecologic Oncology Department at MedStar Washington 
      Cancer, Washington, District of Columbia, USA.
FAU - Sugarbaker, Paul H
AU  - Sugarbaker PH
AD  - Chief of Peritoneal Surface Malignancy Program and Director of the Center for 
      Gastrointestinal Malignancies, MedStar Washington Cancer Institute, Washington, 
      District of Columbia, USA.
LA  - eng
GR  - Merck Sharp & Dohme/
PT  - Journal Article
DEP - 20201025
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - Granulosa cell tumor of the ovary
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Combined Modality Therapy
MH  - Cytoreduction Surgical Procedures
MH  - Female
MH  - Follow-Up Studies
MH  - *Granulosa Cell Tumor/drug therapy
MH  - Humans
MH  - *Hyperthermia, Induced
MH  - Hyperthermic Intraperitoneal Chemotherapy
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Peritoneal Neoplasms
MH  - Review Literature as Topic
OTO - NOTNLM
OT  - cytoreductive surgery
OT  - granulosa cell tumor
OT  - hyperthermic intraperitoneal chemotherapy
OT  - peritoneal metastases
OT  - recurrence
EDAT- 2020/10/27 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/10/26 05:31
PHST- 2020/07/11 00:00 [received]
PHST- 2020/08/25 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/10/26 05:31 [entrez]
AID - 10.1111/jog.14494 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2021 Jan;47(1):44-51. doi: 10.1111/jog.14494. Epub 2020 
      Oct 25.